CT3021 / Crossignal Therap - LARVOL DELTA

Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist (AACR 2024) - "CT3021 is well tolerated in rats after repeat dosing. Further toxicology and efficacy studies are underway to explore the potential of CT3021 as a best-in-class adenosine receptor antagonist immunotherapy for the treatment of CD73 positive and A1 receptor positive solid tumors."

IO biomarker • Late-breaking abstract • Oncology • Solid Tumor • ADORA2A • CD73